A new approach to modeling covariate effects and individualization in population pharmacokinetics-pharmacodynamics

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 33, Issue 1, 2006, Pages 49-74

  Tze, Leung Lai ^a   Shih, Mei Chiung ^b   Wong, Samuel P ^c  

^a STANFORD UNIVERSITY   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Hybrid estimator; Mixed effects model; Neural network; Regression splines

Indexed keywords

ANALYTICAL PARAMETERS; ARTICLE; ARTIFICIAL NEURAL NETWORK; CONCENTRATION (PARAMETERS); DRUG EFFECT; MATHEMATICAL COMPUTING; MEASUREMENT; MODEL; MONTE CARLO METHOD; NONLINEAR SYSTEM; NONPARAMETRIC TEST; PRIORITY JOURNAL; REGRESSION ANALYSIS; SIMULATION; STATISTICAL ANALYSIS;

ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; DACARBAZINE; HUMANS; MODELS, BIOLOGICAL; MONTE CARLO METHOD; NEURAL NETWORKS (COMPUTER); PHARMACOKINETICS; PHARMACOLOGY; REGRESSION ANALYSIS;

EID: 33645856172     PISSN: 1567567X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10928-005-9000-2     Document Type: Article

References (28)

1. S. L. Beal and L. B. Sheiner. NONMEM User's Guide. NONMEM Project Group, University of California, San Francisco (1992).
2. M. J. Lindstrom and D. M. Bates. Nonlinear mixed effects models for repeated measures data. Biometrics 46:673-687 (1990).
3. J. C. Pinheiro and D. M. Bates. Mixed-effects Models in S and S-Plus. Springer-Verlag, New York, 2000.
4. A. Yafune, M. Takebe, and H. Ogata. A use of Monte Carlo integration for population pharmacokinetics with multivariate population distribution. J. Pharmacokin. Biopharm. 26:103-123 (1998).
5. M. Davidian and A. R. Gallant. Smooth nonparametric maximum likelihood estimation for population pharmacokinetics, with applications to quindine. J. Pharmacokin. Biopharm. 20:529-556 (1992).
6. K. E. Fattinger, L. B. Sheiner, and D. Verotta. A new method to explore the distribution of interindividual random effects in nonlinear mixed effects models. Biometrics 51:1236-1251 (1995).
7. L. S. Magder and S. L. Zeger. A smooth nonparametric estimate of a mixing distribution using mixture of gaussians. J. Am. Statist. Assoc. 91:1141-1151 (1996).
8. U. Wahlby, E. N. Johnsson, and M. O. Karlsson. Assessment of actual significance levels for covariate effects in NONMEM. J. Pharmacokin. Biopharm. 28:231-252 (2001).
9. U. Wahlby, M. R. Bouw, E. N. Jonsson, and M. O. Karlsson. Assessment of type I error rates for the statistical sub-model in NONMEM. J. Pharmacokin. Biopharm. 29:251-269 (2002).
10. J. V. Gobburu and J. Lawrence. Application of resampling techniques to estimate exact significance levels for covariate selection during nonlinear mixed effects model building: some inferences. Pharm. Res. 19:92-98 (2002).
11. T. L. Lai and M. C. Shih. A hybrid estimator in nonlinear and generalised linear mixed effects models. Biometrika 90:859-879 (2003).
12. T. L. Lai and M. C. Shih. Nonparametric estimation in nonlinear mixed effects models. Biometrika 90:1-13 (2003).
13. T. J. Hastie and R. J. Tibshirani. Generalized Additive Models. Chapman and Hall, New York, 1990.
14. D. R. Cox and E. J. Snell. A general definition of residuals. J. R. Statist. Soc. B. 30:248-75 (1968).
15. A. Mallet. A maximum likelihood estimation method for random coefficient regression models. Biometrika 73:645-656 (1986).
16. A. Mallet. A nonparametric method for population pharmacokinetics: A case study. Proc. Biopharm. Sec. Am. Statist. Assoc. 11-20 (1992).
17. F. Mentré and A. Mallet. Handling covariates in population pharmacokinetics. Int. J. Biomed. Comput. 36:25-33 (1994).
18. J. W. Mandema, D. Verotta, and L. B. Sheiner. Building population pharmacokinetics-pharmacodynamic models. I. Models for covariate effects. J. Pharmacokin. Biopharm. 20:511-528 (1992).
19. C. Kooperberg, S. Bose, and C. J. Stone. Polychotomous regression. J. Amer. Statist. Assoc. 92:117-127 (1997).
20. C. de Boor. A Practical Guide to Splines. Revised Edition. Springer-Verlag, New York, 2001.
21. J. H. Friedman. Multivariate adaptive regression splines (with discussion). Ann. Statist. 1:1-141 (1991).
22. C. J. Stone. The use of polynomial splines and their tensor products in multivariate function estimation. Ann. Statist. 22:118-184 (1994).
23. A. R. Barron. Universal approximation bounds for superpositions of a sigmoidal function. IEEE Trans. Info. Theor. 39:930-945 (1993).
24. B. Efron and R. J. Tibshirani. An Introduction to the Bootstrap, Chapman and Hall, New York, 1993.
25. T. L. Lai and L. Zhang. Statistical analysis of ligand-binding experiments. Biometrics 50:782-797 (1994).
26. P. O. Maitre, M. Buhrer, D. Thomson, and D. R. Stanski. A three-step approach combining Bayes regression and NONMEM population analysis: application to midazolam. J. Pharmacokin. Biopharm. 19:377-384 (1991).
27. J. F. Jen, D. L. Cutler, S. M. Pai, V. K. Batra, M. B. Affrime, D. N. Zambas, S. Heft, and G. Hajian. Population pharmacokinetics of temozolomide in cancer patients. Pharm. Res. 17:1284-1289 (2000).
28. E. S. Newlands, G. R. P. Blackledge, J. A. Slack, G. J. S. Rustin, D. B. Smith, N. S. A. Stuart, C. P. Quarterman, R. Hoffman, M. F. G. Stevens, M. H. Brampton, and A. C. Gibson. Phase I trial of temozolomide. Brit. J. Cancer 65:287-291 (1992).